Figure 7.
Cumulative incidence of progression to advanced myelodysplastic syndrome (MDS) for patients with refractory anemia and either normal karyotype, monosomy 7, or trisomy 8 or other abnormalities at the time of diagnosis. Patients who had received stem cell transplantation were censored at time of transplantation.17